CA2095439A1 - Substance that stops any bleeding on contact for medical, surgical and dental uses - Google Patents

Substance that stops any bleeding on contact for medical, surgical and dental uses

Info

Publication number
CA2095439A1
CA2095439A1 CA 2095439 CA2095439A CA2095439A1 CA 2095439 A1 CA2095439 A1 CA 2095439A1 CA 2095439 CA2095439 CA 2095439 CA 2095439 A CA2095439 A CA 2095439A CA 2095439 A1 CA2095439 A1 CA 2095439A1
Authority
CA
Canada
Prior art keywords
contact
blood
bleeding
coagulation
pathways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2095439
Other languages
French (fr)
Other versions
CA2095439C (en
Inventor
Leslie Binshyang Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2095439A1 publication Critical patent/CA2095439A1/en
Application granted granted Critical
Publication of CA2095439C publication Critical patent/CA2095439C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof

Abstract

There is disclosed a method for stopping bleeding and forming black blood coagulation on contact, comprising administering powdered L-threo-hex-2-enono-1,4-lactone thereof to a wound site in an amount of 0.1568 grams for every milliliter of blood. This includes cancer, liver disease and hemophiliac bleeding in patients or animals in whom the thrombocytopenia or coagulation factor disorders result. Accordingly, the said mechanism of action of powdered L-threo-hex-2-enono-1,4-lactone in the formation of blood coagulation on contact is the unique common pathway for all blood coagulations, which overturns the mechanisms of intrinsic and extrinsic pathways for blood coagulation cascade being the unique pathways for blood coagulation in which the coagulation factors 1, 2, 5, 7, 8, 9, 10 and platelet factor 3 are essential for the pathways.
CA 2095439 1990-12-06 1991-12-05 Substance that stops any bleeding on contact for medical, surgical and dental uses Expired - Fee Related CA2095439C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62409490A 1990-12-06 1990-12-06
US07/624,094 1990-12-06

Publications (2)

Publication Number Publication Date
CA2095439A1 true CA2095439A1 (en) 1992-06-07
CA2095439C CA2095439C (en) 1998-12-08

Family

ID=24500629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2095439 Expired - Fee Related CA2095439C (en) 1990-12-06 1991-12-05 Substance that stops any bleeding on contact for medical, surgical and dental uses

Country Status (5)

Country Link
EP (1) EP0644754A4 (en)
AU (1) AU662505B2 (en)
CA (1) CA2095439C (en)
NO (1) NO930858D0 (en)
WO (1) WO1992010999A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334933A (en) * 1971-02-19 1973-10-24 Ahrens G W Reaction products of caldium ascorbate and preparation containing them
FR2336925A1 (en) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc.
JPS6029361B2 (en) * 1977-03-04 1985-07-10 白井松新薬株式会社 Pharmaceutical composition with enhanced hemostatic effect
US4959362A (en) * 1983-12-19 1990-09-25 Takeda Chemical Industries, Inc. Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
NO161779C (en) * 1986-04-22 1989-10-04 Olav Johan Braenden PROCEDURE FOR PREPARING AN ANTI-COOLING PREPARATION.
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions

Also Published As

Publication number Publication date
AU662505B2 (en) 1995-09-07
EP0644754A1 (en) 1995-03-29
AU9103491A (en) 1992-07-22
EP0644754A4 (en) 1995-12-27
WO1992010999A1 (en) 1992-07-09
NO930858D0 (en) 1993-03-09
CA2095439C (en) 1998-12-08

Similar Documents

Publication Publication Date Title
ATE515265T1 (en) VITAMIN D AND ITS ANALOGUES FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISEASES
DE69016755T2 (en) Delayed-release pharmaceutical preparation for the treatment of periodontal diseases.
NL990012I1 (en) Medicines containing salmeterol and fluticasone.
EE02971B1 (en) Use of droloxyfene or its salts in the manufacture of a medicament for the treatment of bone diseases
DE69232263T2 (en) RADICAL RECIPIENT ("SPIN TRAPS") FOR TREATING ILLNESSES ASSOCIATED WITH OXIDATION OF LIPIDES AND PROTEINS
DE69002718T2 (en) Medication.
EP0376251A3 (en) An anticoagulant substance obtained from urine
ATE133859T1 (en) SUSTAINED-RELEASE PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF PERIODONTAL DISEASES
BR9913746E8 (en) pyridinium derivative, compound preparation process, compound use, pharmaceutical composition for treating diabetic complications and aging-related diseases, process for preparing a parenteral formulation, process for treating a diabetic patient by rupturing an age preformed within the patient, and process for preventing or treating diseases caused by diabetes and aging-related complications.
Al-Chalabi et al. Value of a single intraperitoneal dose of heparin in prevention of adhesion formation: an experimental evaluation in rats
ATE88633T1 (en) USE OF CERTAIN CALCIUM CITRATE MALATE IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS.
ATE89737T1 (en) TREATMENT OF LEUKOCYTE DISORDERS WITH GM-CSF.
EP0429522A4 (en) Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
CA2095439A1 (en) Substance that stops any bleeding on contact for medical, surgical and dental uses
AU3401093A (en) Therapeutic agent for threatened abortion
DE69314586D1 (en) Medicament composition containing TCF-II
EP0402208B1 (en) Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect
ATE161016T1 (en) PROPHYLACTIC/THERAPEUTIC COMPOSITION CONTAINING WS7622A FOR THE PREVENTION AND TREATMENT OF SCATTERED, INTRAVASCULAR COAGULATION, CHRONIC, INFECTIOUS RESPIRATORY DISEASES OR CHRONIC BRONCHITIS
ATE299496T1 (en) PYRIDINIUM COMPOUNDS FOR THE TREATMENT OF AGE-RELATED DISEASES
US6783774B1 (en) Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses
ATE79750T1 (en) ANTI-CANCER PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER.
DK417889D0 (en) USE OF 2-AZABICYCLO (2.2.2.) - CARBOXYLIC ACID DERIVATIVES FOR THE MANUFACTURE OF MEDICAL PRODUCTS FOR THE TREATMENT OF VASCULAR DISEASES
Kukletová et al. Oxazepam to stomatologic patients who do not cooperate.
RU95113002A (en) METHOD FOR TREATING ACUTE SURGICAL DISEASES OF ABDOMINAL BODIES
PT95867A (en) Process for the preparation of a delayed-release composition comprising a lactide and glycolide copolymer, for treatment of periodontal diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed